Anna R Minchom

19PUBLICATIONS

237CO-AUTHORS

Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunologyMolecular targetsPredictive and prognostic markersNanomedicine

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (19)

Sort by Publication Date:

|Jun 08, 2026

First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignancies.

|Apr 27, 2026

Phase I trial of Ipatasertib plus Atezolizumab enhances PI3K/AKT pathway immune responses in solid tumors and refractory glioblastoma.

|Mar 14, 2026

Drug Development in Non-Oncogene-Addicted Non-Small Cell Lung Cancer.

Pedro Cruz, Cristina Boixareu, Diogo J Silva

|Jan 23, 2026

International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROR.

Emily Alger, Olalekan Lee Aiyegbusi, Amylou C Dueck

|Aug 01, 2025

Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors.

Jia Liu, Anna R Minchom, Alastair Greystoke

|Jun 27, 2025

Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial.

Susana Banerjee, Matthew G Krebs, Alastair Greystoke

Pageof 4

Frequent Collaborators

Udai Banerji

Christina Yap

Juanita Lopez

Bora Gurel

Mona Parmar

Johann de Bono

Ruth Ruddle

Ruth Riisnaes

Andrea Biondo

Susana Banerjee

Frequent Collaborators

Udai Banerji

Christina Yap

Juanita Lopez

Bora Gurel